ISPOR - PMS39 Cost-Effectiveness Analysis of Certolizumab Pegol in Patients With Rheumathoid Arthritis from a Brazilian Private Perspective

Full Text

PMS39 Cost-Effectiveness Analysis of Certolizumab Pegol in Patients With Rheumathoid Arthritis from a Brazilian Private Perspective

Abstract

Authors

T. Piha E.D.S. Meirelles W. Kuriki P.A. Miranda

Back to Volume 15, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now